MacroGenics, Inc. is focused on the development of improved immunotherapeutic products, including monoclonal antibodies and vaccines and has identified new targets for the treatment of cancer and inflammatory disorders and the prevention of infectious diseases. The company has an important strategic partnership with Genzyme.
